Influence of Oral Hp Infection and Oral Related Factors on Gastric Hp Infection and Eradication Therapy (Hp)
Helicobacter Pylori Infection
About this trial
This is an interventional prevention trial for Helicobacter Pylori Infection focused on measuring Helicobacter pylori, Oral hygiene, Dental caries, Risk factor, Saliva Test Cassette
Eligibility Criteria
Inclusion Criteria:
The first stage:Study the prevalence and risk factors of oral and gastric H. pylori infection 1. No obstacle to understanding the content of the questionnaire, and can answer the questions accurately, 2. Voluntarily participate in this research and sign the informed consent. The second stage:Study the status and influencing factors of eradication therapy of oral and gastric H. pylori
- >18 years old,
- Initial H. pylori eradication therapy,
- No obstacle to understanding the content of the questionnaire, and can answer the questions accurately,
- Agree to perform eradication treatment and receive telephone follow-up, and sign the informed consent.
Exclusion Criteria:
The first stage:Study the prevalence and risk factors of oral and gastric H. pylori infection
- History of taking proton pump inhibitors (PPI), H2 receptor blockers and bismuth agent within two weeks before enrollment,
- History of taking antibiotics and Chinese medicines with antibacterial effect within one month before enrollment,
- Complete or partial gastrectomy,
- Edentulous. The second stage:Study the status and influencing factors of eradication therapy of oral and gastric H. pylori
1. Allergic to penicillin, clarithromycin, ilaprazole, colloidal bismuth tartrate, 2. Complete or partial gastrectomy, 3. Oral scaling within 6 months, 4. Edentulous.
Sites / Locations
- The second affiliated hospital of Xi'an Jiaotong universityRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
No Intervention
No Intervention
Experimental
Experimental
oral H. pylori negative and gastric H. pylori negative group
oral H. pylori positive and gastric H. pylori negative group
oral H. pylori negative and gastric H. pylori positive group
oral H. pylori positive and gastric H. pylori positive group
These people are tested negative for C13-urea breath test (C13-UBT) and negative for H. pylori Saliva Test Cassette (HPS).
These people are tested negative for C13-urea breath test (C13-UBT) and positive for H. pylori Saliva Test Cassette (HPS).
These patients are tested positive for C13-urea breath test (C13-UBT) and negative for H. pylori Saliva Test Cassette (HPS),they are given PPI quadruple therapy for 14 days. After 4-6 weeks of completing eradication therapy, 13C-UBT will be performed to confirm the results of gastric H. pylori eradication.At the same time, Patients with successful eradication will be instructed to conduct 13C-UBT examination after 1year to confirm whether the recurrence of gastric H. pylori.
These patients are tested positive for C13-urea breath test (C13-UBT) and positive for H. pylori Saliva Test Cassette (HPS),they are given PPI quadruple therapy for 14 days. After 4-6 weeks of completing eradication therapy, 13C-UBT will be performed to confirm the results of gastric H. pylori eradication, and the oral H. pylori infection will be re-detected by HPS.At the same time, Patients with successful eradication will be instructed to conduct 13C-UBT examination after 1year to confirm whether the recurrence of gastric H. pylori.